Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis and Francisella tularensis antibodies

N. Parthasarathy*, R. Saksena, P. Kováč, D. DeShazer, S. J. Peacock, V. Wuthiekanun, H. S. Heine, A. M. Friedlander, C. K. Cote, S. L. Welkos, J. J. Adamovicz, S. Bavari, D. M. Waag

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


We developed a microarray platform by immobilizing bacterial 'signature' carbohydrates onto epoxide modified glass slides. The carbohydrate microarray platform was probed with sera from non-melioidosis and melioidosis (Burkholderia pseudomallei) individuals. The platform was also probed with sera from rabbits vaccinated with Bacillus anthracis spores and Francisella tularensis bacteria. By employing this microarray platform, we were able to detect and differentiate B. pseudomallei, B. anthracis and F. tularensis antibodies in infected patients, and infected or vaccinated animals. These antibodies were absent in the sera of nai{dotless}̈ve test subjects. The advantages of the carbohydrate microarray technology over the traditional indirect hemagglutination and microagglutination tests for the serodiagnosis of melioidosis and tularemia are discussed. Furthermore, this array is a multiplex carbohydrate microarray for the detection of all three biothreat bacterial infections including melioidosis, anthrax and tularemia with one, multivalent device. The implication is that this technology could be expanded to include a wide array of infectious and biothreat agents.

Original languageEnglish
Pages (from-to)2783-2788
Number of pages6
JournalCarbohydrate Research
Issue number16
Publication statusPublished - 3 Nov 2008
Externally publishedYes

Bibliographical note

Funding Information:
The research described herein was sponsored by the US Army Medical Research and Materiel Command under projects 2.10018_06_RD-B, 2.10019_07_RD-B and 5.10023_08_RD-B. The authors thank Sarah L. Norris for statistical analysis. The authors also thank Dr. Sharan VedBrat (KamTek Inc., Gaithersburg, MD) for carbohydrate printing. The support of staff at Sappasithiprasong Hospital, Ubon Ratchathani, and the Mahidol Oxford Tropical Medicine Research Unit, particularly Dr. Direk Limmathurotsakul and Dr. Allen Chang, is gratefully acknowledged. S.P. is funded by a Welcome Trust Career Development fellowship in Clinical Tropical Medicine. The use of human serum samples was approved by the Human Use Committee (FY 06-36, HP-06-36). Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 1996. The facility where this research was conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Opinions, interpretations, conclusions and recommendations are those of the authors and not endorsed by the US Army.


  • Bacillus anthracis (anthrax)
  • Burkholderia pseudomallei (melioidosis)
  • Carbohydrate microarray
  • Francisella tularensis (tularemia)
  • Serum antibodies


Dive into the research topics of 'Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis and Francisella tularensis antibodies'. Together they form a unique fingerprint.

Cite this